Pharm endocrine (Bone) drugs Flashcards
1
Q
3 main hormones Ca+2/phosphate homeostatis
A
- PTH - GI tract, Kidney tubule, Bone - Mech of action = Ca+2 & phosphate increase w/Vit D action (GI) -> Ca+2 increase & Phosphat decrease (kidney)
- VIT D- Gi tract, bone, Parathyroid gland- Mech of action = Ca+2 & phosphat increase (GI), PTH decrease (PT)
- FGF-23- Kidney, GI, bone - Mech of action= Decrease Pi & calcitriol (kidney), Decrease Ca+2, Pi absorption Via low Calcitriol secretion (GI), Mineralization of Bone matrix
2
Q
Vit D supplements
A
- Cholecalciferol = Vit D3 (meat)
- Ergocalciferol = Vit D2 (plant)
- Ergo - used for food fortification (enrichment), available for high dose injection
- MOA = reg gene transcription via Vit D receptor
- Clinical Uses:
- Oral admin to treat Vit D def
- Secondary HYPERparathryroidism (Increased PTH due to hypocalcemia)
- HYPOparathryroidism (HIGH doses, combo w/calcium supplements)
- Rickets & osteomalacia
- Osteoporosis (w/ca+2)
3
Q
Vit D Adverse Effects
A
- Hypercalcemia - bypassing feedback regulation maintains normal levels
- Hyperphosphatemia
- Hypercalciuria
- Drug interactions:
- Aluminum - in form of antacids (interferes w/ Absorption)
- Atorvastatin (lipitor) - Vit D decrease plasma conc of atorvastatin
- Decrease effectiveness of **CYP 3A4 meds **
- Thiazide antidiuretics (block Na/Cl- transporter) can lead to hypercalcemia
- Cardio drugs = digitoxin, dilitiazem (BP meds)
4
Q
Vit D analogues
A
- _Calcitriol (D3 meat) _
- Management of secondary hyperpara in pts with kideney disease
- management of hypocalcemia in pts w/hypoparathyroid
- May cause more hypercalcemia than _paricalcitol _
- Doxercalciferol (D2 vege)
- Used to treat secondary hyperparathryroid (increase PTH due to low serum Ca+2) in pts with kidney disease
- Paricalcitol (D3 meat)
- Analog of calcitriol used for secondary hyperparathyroid in pts with kidney disease on DIALYSIS
- Calcipotriene: analog of calcitriol
- Research for dermatological use inflammatory disease - NO apply face
5
Q
Vit D considerations
A
- Is considered secosteroids:
- Lipophilic compounds - orally absorbed - sequestered in fat (obesity lead to vit D def)
- Drug interaction - Sunscreen
- Parent compound NOT bioactive, adverse effects (toxicity) from VIT D itself are rare.
- Overdose may happen when enough 25OH-D is made to active receptors = VITD overload
- Symptoms:
- Confusion, nausea, constipation, thrist, urination
- Labs = PTH lvl undectable, Increase ca+2 serum & urine
6
Q
Alendronate
A
- Analogues of pyrophosphate
- Sit upright/stand for 30-60 min to take
- MOA:
- supresses activity of osteoclasts = inhibits bone reabsorption
- Clinical uses:
- Osteoporosis
- Paget’s disease
- Adverse effects:
- Adynamic bone (reduced osteroblast & clasts)
- Eophageal irritation
- RARE: osteonecrosis of Jaw
- Similar:
- Risedronate, ibandronate, pamidronate
7
Q
Bisphophonates
A
- Impair ability of osteoclasts to form ruffled border
- Impair osteoclasts to adhere to bony surface
- Inhibit osteoclasts ability to produce protons necessary for bone reabsoption
- Promote osteoclast apoptosis
- Daily oral = Alendronate, Risdronate, Ibandronate
- Weekly oral = Alendronate, Risedronate
- Monthly oral = Ibandronate
- Quarterly inject = Ibandronate
- Annual infusion = Zoledronate
8
Q
Pamidronate & Zoledronate
A
- Clinical use:
- Osteolytic lesions of multiple myeloma & breast cancer - due to overexpression of RANKL (osteoclast activation)
- Hypercalcemia assoc w/malingnancy
- IV only
- Osteonecrosis of JAW most common
9
Q
RANKL atagonists - Denosumab (-)
A
- MOA
- Monoclonal antibody targets receptor activator of nuclear factor kappa-B ligand (RANKL)
- Clinical uses:
- Osteoporosis prevention/treatment - SC injection every 6 months
- Adverse effects:
- Jaw osteonecrosis in cancer pts (breast cancer)
- Hypocalcemia
10
Q
Raloxifene
A
- Selective estrogen-receptor modulator (SERM) - oral admin
- MOA:
- Esterogen agonist effect in bone
- Estrogen antagonist effects in breast & endometrium
- Clinical uses:
- Osteoporosis in post menopausal women
- Decreases breast cancer
- Adverse effects:
- Hot Flashes
- Thromboembolism - CONTRAindicated in women w/history DVT
11
Q
Teriparatide (PTH)
A
- MOA:
- Acts through PTH receptors to increase bone formation by osteroblasts
- Clinical uses:
- Severe osteroporosis
- Adverse effects
- Hypercalcemia
- Hypercalciuria
- Osteoscelorosis & osteosarcoma (tumor in mesenchymal space bone)
- Leg cramps
- SC injection daily BEST for osteoporosis
12
Q
Teriparatide (hPTH 1-34)
A
- PTH analogue
- Contraindications:
- Open epiphyses
- prior radiation therapy
- Paget’s disease
- Hypercalcemia
- Similar = hPTH 1-84 & Fluoride for osteoporosis
13
Q
Calcitonin
A
- SC injection or intranasal admin (SC injection lowers serum Ca+2 hours)
- MOA:
- Acts through calcotonin receptors = inhibit bone resorption by osteoclasts
- ALSO inhibits Ca+2 absorption in GI & reabsorption in kidneys
- Clinical uses:
- Postmeno osteoporosis (NOT 1st line)
- Hypercalcemia
- Adverse effects:
- Rhinitis w/nasal spray
- Flushing, nausea, diarrhea
14
Q
Cinacalet
A
- Oral admin ONLY
- MOA: increases sensitivity to Ca+2 sensing receptor to Ca+2 in PT cells = decrease of PTH
- Clinical use:
- Chronic kidney disease - secondary hyperparathyroid
- Hypercalcemia associated w/ parathryroid carcinoma
- Adverse effects:
- Nausea, dizziness
- hypocalcemia
- Adynamic bone (issues w/kidneys Low osteoblast & clast)
15
Q
Sevelamer (phosphate binder)
A
- MOA
- Decreases GI absoption of inorganic phosphate
- Lowers serum cholesterol binding to bile acids
- Clinical uses:
- Chronic kidney disease
- Hypoparathyroidism
- VIt D intoxication
- Tumoral calcinosis (calcium deposits in soft tissue)
- Hyperphosphatemia (hyperotosis syndrome)
- Adverse effects:
- Constipation
- Thrombosis
- Hypertension
16
Q
Al hydroxide & Ca+2 carb/acetate (phosphate binders)
A
- Al hydroxide: Rarely USED due to effects
- Ca+2 carbonate & acetate: Similiar to sevelamar
- Acidic gastric PH required for Ca+2 carbonate (CaCO3) absorption
17
Q
Calcium Supplements
A
- MOA: essential for bone mineralization
- Preps:
- Ca+2 gluconate (IV)
- Ca+2 carbonate (oral)
- Ca+2 citrate-malate (oral)
- Clinical uses:
- Secondary hyperpara (High PTH due to low serum Ca+2)
- Hypoparathyroidism
- Rickets / oseomalacia
- Adverse effects:
- Constipation
- Hypercalciuria
- Hypercalcemia
- Renal Calculi
- Considerations: Needs to be taken with food (better absorption GI)
18
Q
Inorganic Phosphate
A
- MOA:
- Essesntial for bone mineralization
- Clinical uses:
- Severe Hypophosphatemia (LOW phosphate in blood)
- Adverse effects:
- Diarrhea
- K+ phosphate preferred over sodium phosphate - minimize renal excretion of phosphate OR correct coexisting hypokalemia